Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more
Coherus BioSciences Inc (CHRS) - Total Assets
Latest total assets as of December 2025: $258.34 Million USD
Based on the latest financial reports, Coherus BioSciences Inc (CHRS) holds total assets worth $258.34 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Coherus BioSciences Inc - Total Assets Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Coherus BioSciences Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Coherus BioSciences Inc's total assets of $258.34 Million consist of 74.8% current assets and 25.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.4% |
| Accounts Receivable | $17.82 Million | 6.9% |
| Inventory | $3.17 Million | 1.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $46.24 Million | 17.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Coherus BioSciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Coherus BioSciences Inc's current assets represent 74.8% of total assets in 2025, a decrease from 93.5% in 2012.
- Cash Position: Cash and equivalents constituted 34.4% of total assets in 2025, down from 54.8% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 17.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is intangible assets at 17.9% of total assets.
Coherus BioSciences Inc Competitors by Total Assets
Key competitors of Coherus BioSciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Coherus BioSciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Coherus BioSciences Inc generates 0.16x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Coherus BioSciences Inc generates $ 65.04 in net profit.
Coherus BioSciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.21 | 2.40 |
| Quick Ratio | 1.35 | 0.96 | 2.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $52.73 Million | $ 58.60 Million | $ 359.66 Million |
Coherus BioSciences Inc - Advanced Valuation Insights
This section examines the relationship between Coherus BioSciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.03 |
| Latest Market Cap to Assets Ratio | 0.88 |
| Asset Growth Rate (YoY) | -42.4% |
| Total Assets | $258.34 Million |
| Market Capitalization | $226.16 Million USD |
Valuation Analysis
Near Book Valuation: The market values Coherus BioSciences Inc's assets close to their book value ( 0.88x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Coherus BioSciences Inc's assets decreased by 42.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Coherus BioSciences Inc (2012–2025)
The table below shows the annual total assets of Coherus BioSciences Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $258.34 Million | -42.40% |
| 2024-12-31 | $448.53 Million | -28.76% |
| 2023-12-31 | $629.60 Million | +30.94% |
| 2022-12-31 | $480.85 Million | -29.22% |
| 2021-12-31 | $679.33 Million | -19.29% |
| 2020-12-31 | $841.65 Million | +105.82% |
| 2019-12-31 | $408.93 Million | +311.12% |
| 2018-12-31 | $99.47 Million | -38.83% |
| 2017-12-31 | $162.61 Million | -8.89% |
| 2016-12-31 | $178.49 Million | -15.96% |
| 2015-12-31 | $212.38 Million | +13.44% |
| 2014-12-31 | $187.22 Million | +294.59% |
| 2013-12-31 | $47.45 Million | +78.82% |
| 2012-12-31 | $26.53 Million | -- |